ANNX

AnnexonA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$15.50

Analysis reference price unavailable

Analysis 2026-09-11 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$7.00

Analysis reference price unavailable

Analysis 2026-09-11 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$1.50

Analysis reference price unavailable

Analysis 2026-09-11 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-11

AI commentary

Company-source tone is constructive and the late-2026 milestone calendar is dense, but independent coverage is thin. Reliable post-update price reaction, analyst revisions, options positioning, short interest, employee sentiment, and sufficient social coverage are unavailable; the zero-valued fields above indicate unavailable inputs rather than neutral readings. Sentiment supports cautious monitoring rather than a high-conviction directional call.

RankAlpha Sentiment Codex - 2026-09-11

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-11-30eventANX1502 proof-of-concept resultsHigh impact

Proof-of-concept data for the oral C1 inhibitor ANX1502 are expected in fall 2026. Positive results could broaden perceived platform value, although this earlier-stage program should carry less valuation weight than the Phase 3 assets [#SEC-8K-2026-08-12].

2026-12-31eventARCHER II Phase 3 geographic-atrophy dataHigh impact

Month-15 primary-endpoint data for vonaprument remain on track for Q4 2026. This is the largest near-term valuation catalyst and carries substantial binary clinical risk [#SEC-8K-2026-08-12].

2026-12-31eventTanruprubart U.S. BLA submissionHigh impact

Annexon expects to submit a U.S. BLA for tanruprubart in Guillain-Barré syndrome during Q4 2026, while its European application is under review. Submission execution and regulators' assessment of the evidence package remain key uncertainties [#SEC-8K-2026-08-12].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-11 • Updated nightlySource: Internal modelMethodology